Advances in Cancer Immunotherapy™ - Princeton, NJ

Specifically designed for clinical oncologists and the entire team involved in treating cancer patients with immunotherapy, this program will provide an understanding of basic immunology principles underlying the clinical application of immunotherapy, provide insights into the indications and clinical management of patients receiving tumor immunotherapy and discuss emerging drugs and concepts in the tumor immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, this program will summarize central themes in tumor immunotherapy, describe the latest research advances and focus on currently approved tumor immunotherapy approaches to facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) management of side effects, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.

Attendees can also take advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts and clinical oncologists and other health care providers from the surrounding community.

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics
Basic Mechanisms of Tumor Immune Suppression
Basic Principles of Tumor Immunotherapy
Current Status of Chimeric and Adoptive T Cell Therapy
Cytokines: Interferons, Interleukins and Beyond
Immunology 101 for the Non-Immunologist
Immunotherapy for the Treatment of Brain Metastases
Immunotherapy for the Treatment of GU Malignancies
Immunotherapy for the Treatment of Hematologic Malignancies
Immunotherapy for the Treatment of Melanoma
Immunotherapy for the Treatment of Non-Small Cell Lung Carcinoma
Is there a Role for Radiation Therapy and Immunotherapy?
Oncolytic Viruses as Tumor Immunotherapy Agents
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies

+ show speakers and program
Program Schedule

7:00 am – 8:00 am Registration
7:00 am – 8:00 am Continental Breakfast
8:00 am – 8:10 am Welcome and Introductions
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Session I: Principles of Tumor Immunology
1.25 AMA PRA Category 1 Credits™
8:10 am – 8:35 am Immunology 101 for the Non-Immunologist
Derek B. Sant’Angelo, PhD – Rutgers Cancer Institute of New Jersey
8:35 am – 9:00 am Basic Principles of Tumor Immunotherapy
Richard D. Carvajal, MD – Columbia University
9:00 am – 9:25 am Basic Mechanisms of Tumor Immune Suppression
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey
9:25 am – 9:40 am Break
Session II: Major Approaches to Tumor Immunotherapy – What the Clinician Needs to Know
2.5 AMA PRA Category 1 Credits™
9:40 am – 10:05 am Cytokines: Interferons, Interleukins and Beyond
Sanjiv S. Agarwala, MD – St. Luke's Health Cancer Center
10:05 am – 10:30 am Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies
Jedd D. Wolchok, MD, PhD – Memorial Sloan-Kettering Cancer Center
10:30 am – 10:55 am Oncolytic Viruses as Tumor Immunotherapy Agents
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
10:55 am – 11:20 am Is There a Role for Radiation Therapy and Immunotherapy?
Salma K. Jabbour, MD – Rutgers Cancer Institute of New Jersey
11:20 am – 11:45 am Current Status of Chimeric and Adoptive T Cell Therapy
Michel Sadelain, MD, PhD – Memorial Sloan-Kettering Cancer Center
11:45 am – 12:15 pm Panel Discussion
12:15 pm – 1:00 pm Lunch
Session III: The Role of Tumor Immunotherapy for Cancer – Clinical Indications and Patient Management
2.75 AMA PRA Category 1 Credits™
1:00 pm – 1:25 pm Immunotherapy for the Treatment of Non-Small Cell Lung Carcinoma
Hossein Borghaei, MS, DO – Fox Chase Cancer Center
1:25 pm – 1:50 pm Immunotherapy for the Treatment of GU Malignancies
Eric Singer, MD – Rutgers Cancer Institute of New Jersey
1:50 pm – 2:15 pm Immunotherapy for the Treatment of Melanoma
Janice Mehnert, MD – Rutgers Cancer Institute of New Jersey
2:15 pm – 2:30 pm Break
2:30 pm – 2:55 pm Immunotherapy for the Treatment of Hematologic Malignancies
Roger Strair, MD, PhD – Rutgers Cancer Institute of New Jersey
2:55 pm – 3:20 pm Immunotherapy for the Treatment of Brain Metastases
Ann W. Silk, MD, MS – Rutgers Cancer Institute of New Jersey
3:20 pm – 3:45 pm Panel Discussion
3:45 pm – 4:00 pm Closing Remarks
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey and
Jedd D. Wolchok, MD, PhD – Memorial Sloan-Kettering Cancer Center

28 Mar - 28 Mar 2015

Princeton
United States of America
meeting website